RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Show more

Location: 100 Columbia, Aliso Viejo, CA, 92656, United States | Website: https://www.rxsight.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

272.1M

52 Wk Range

$6.32 - $58.23

Previous Close

$6.65

Open

$6.75

Volume

1,353,635

Day Range

$6.73 - $7.45

Enterprise Value

56.32M

Cash

227.5M

Avg Qtr Burn

-4.205M

Insider Ownership

5.56%

Institutional Own.

97.94%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date